A Model Perspective Explanation of the Long-Term Sustainability of a Fully Human BCMA-Targeting CAR (CT103A) T-Cell Immunotherapy

Different from canonical drugs, CAR T-cells are “living drugs”, which derived from patient’s own blood. Studies of the pharmacokinetics of CAR T-cells could improve our understanding of their efficacy, safety, optimal dosage, and other characterizes. We previously reported a phase I study of a novel...

Descripción completa

Detalles Bibliográficos
Autores principales: Mu, Wei, Long, Xiaolu, Cai, Haodong, Chen, Caixia, Hu, Guang, Lou, Yaoyao, Xing, Shugang, Wang, Di, Wang, Jue, Xiao, Min, Wang, Kun, Sun, Zhongyi, Li, Chunrui, Zhou, Jianfeng, Chen, Liting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847740/
https://www.ncbi.nlm.nih.gov/pubmed/35185564
http://dx.doi.org/10.3389/fphar.2022.803693

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847740/
https://www.ncbi.nlm.nih.gov/pubmed/35185564
http://dx.doi.org/10.3389/fphar.2022.803693

Ejemplares similares